Clinical topic addressed by the source article: CDC Ebola update
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
People in affected areas of the Democratic Republic of the Congo (DRC), Uganda, and Kenya; travelers to the DRC or Uganda; and health care workers responding to the outbreak.
Care Setting
Care setting described in the source article.
Key Highlights
As of October 5, the DRC had recorded 8,665 confirmed cases and 4,178 confirmed deaths, with a crude case-fatality proportion of approximately 48.2%.
The outbreak surpassed 1,000 confirmed cases within 40 days of response activation, compared with approximately 235 days in the 2018 DRC outbreak.
Confirmed cases were reported in seven DRC provinces; Sud-Kivu had reported no confirmed cases since May 29.
Additional cases were reported in Uganda, Kenya, and France; the CDC reported no outbreak-associated cases in the United States.
The CDC considers the risk of spread to the United States very low; case counts remain subject to change.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Travelers who have been in the DRC within 21 days of their flight are prohibited from boarding commercial flights bound for the United States, including travelers who transited through the DRC.
The CDC identifies ongoing conflict, population movement, and cross-border travel as factors complicating containment or increasing geographic spread risk.
Patient & Prescribing Data
The article provides outbreak surveillance and travel guidance; it does not report a treatment regimen or prescribing data.
No treatment or medication recommendations are provided. The article reports that shortages of personal protective equipment and limited access to health care, diagnostic testing, laboratory services, and infection prevention supplies have complicated the response.
Clinical Best Practices
Follow CDC travel recommendations for affected DRC provinces and take enhanced precautions when visiting other areas of the DRC or Uganda.
Monitor for symptoms during travel and for 21 days after leaving the DRC or Uganda.
U.S. citizens and nationals who recently visited Uganda or South Sudan, but not the DRC, must enter through designated U.S. airports for enhanced screening.
A phase 2 randomized trial suggests reducing nasal commensal viruses with ribavirin spray may improve allergic rhinitis symptoms while supporting a proposed disease mechanism.
